Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – for primary immune thrombocytopenia (ITP) – thanks to new data reported a
bluebird bio has presented long-term data from its Zynteglo one-time gene therapy for the blood disorder beta-thalassaemia, as the company continues talks with payers in Europe to bring the
Nearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years, according to new figures unveiled this weekend.
A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have set up a filing for the new drug in mid-2019.
Understanding complex scientific studies is often a challenge for patients as well as healthcare professionals, but one that may become easier thanks to artificial intelli
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.